Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.41M | -11.48M | -16.20M | -16.27M | -12.11M |
| Total Depreciation and Amortization | 355.30K | 357.40K | 394.00K | 395.70K | 401.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -473.40K | -476.20K | 1.18M | 1.18M | 2.07M |
| Change in Net Operating Assets | -708.30K | -712.50K | 2.06M | 2.07M | -8.04M |
| Cash from Operations | -12.24M | -12.31M | -12.57M | -12.62M | -17.68M |
| Capital Expenditure | -52.30K | -52.70K | -47.70K | -47.90K | -32.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.23M | 1.24M | 231.10K | 232.10K | 3.99M |
| Cash from Investing | 1.18M | 1.19M | 183.30K | 184.10K | 3.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.18M | -1.18M | -2.23M | -2.23M | -2.23M |
| Issuance of Common Stock | -- | -- | 24.50K | 24.50K | 7.47M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.37M | -1.38M | -2.56M | -2.58M | 5.94M |
| Foreign Exchange rate Adjustments | -147.10K | -148.00K | 40.70K | 40.90K | 579.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.58M | -12.65M | -14.91M | -14.97M | -7.20M |